Business Context and Reporting Period
This Form 8-K was filed by Tokai Pharmaceuticals, Inc. on June 9, 2015. The report discloses the entry into a material definitive agreement regarding office space in Boston, Massachusetts.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses solely on the terms of a new lease agreement.
- Lease Payment: $69,916.87 per month in fixed payments.
- Additional Costs: Pro rata share of property taxes and operating expenses.
- Space: 15,981 square feet.
Material Changes
The Company entered into a direct lease with 255 State Street, LLC, replacing its current sublease arrangement which expires on December 31, 2016. The new lease term commences on January 1, 2017, and expires on August 31, 2018.
Outlook, Risks, and Contingencies
Termination Risks: The Landlord may terminate the Lease if the Company fails to remedy a breach of obligations within specified time periods, or upon the Company's bankruptcy or insolvency.
Management Commentary: The filing states that the description of the Lease is not complete and is qualified by reference to the full agreement, which will be filed as an exhibit to the next periodic report.
Investor Verification Checklist
- Verify the full text of the Lease agreement in the next periodic report to review all covenants and termination clauses.
- Confirm the total estimated annual cost including the pro rata share of taxes and operating expenses.
- Assess the impact of the fixed monthly payment on the Company's future cash flow projections.
- Note the discrepancy between the metadata company name (Eledon Pharmaceuticals) and the filing entity (Tokai Pharmaceuticals, Inc.).